By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell technology company Cellular Dynamics International and Madison, Wisconsin-based life sciences company Promega today announced plans to collaborate on validating predictive drug discovery toxicity tests that rely on CDI's induced pluripotent stem cells and cytotoxicity and cell viability assays from Promega.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.